Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines.

Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR.

J Chem Biol. 2017 May 11;10(3):129-141. doi: 10.1007/s12154-017-0169-9. eCollection 2017 Jul.

2.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Apr 1;126(4):1606. doi: 10.1172/JCI86862. Epub 2016 Apr 1. No abstract available.

3.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Jan;126(1):169-80. doi: 10.1172/JCI82066. Epub 2015 Nov 30. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1606.

4.

JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.

Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, Joyce S, Lui VW, Zeng Y, Chiosea SI, Grandis JR.

Neoplasia. 2015 Mar;17(3):256-64. doi: 10.1016/j.neo.2015.01.003.

5.

Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.

Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR.

Mol Med. 2014 Mar 18;20:46-56. doi: 10.2119/molmed.2013.00104.

6.

Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR.

Neoplasia. 2012 Nov;14(11):1005-14.

7.

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.

Autophagy. 2012 Dec;8(12):1873-4. doi: 10.4161/auto.22185. Epub 2012 Sep 20.

8.

Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.

Clin Cancer Res. 2012 Oct 15;18(20):5639-49. doi: 10.1158/1078-0432.CCR-12-1213. Epub 2012 Aug 28.

9.

Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL.

Oral Oncol. 2012 Nov;48(11):1136-45. doi: 10.1016/j.oraloncology.2012.05.015. Epub 2012 Jun 23.

10.

First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR.

Cancer Discov. 2012 Aug;2(8):694-705. doi: 10.1158/2159-8290.CD-12-0191. Epub 2012 Jun 20.

11.

Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.

Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR.

Mol Cancer Ther. 2012 Jun;11(6):1236-46. doi: 10.1158/1535-7163.MCT-11-0936. Epub 2012 Apr 5.

12.

Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.

Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR.

Cancer Prev Res (Phila). 2011 Feb;4(2):230-7. doi: 10.1158/1940-6207.CAPR-10-0249. Epub 2010 Dec 16.

13.

Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.

Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR.

Carcinogenesis. 2009 Nov;30(11):1848-56. doi: 10.1093/carcin/bgp211. Epub 2009 Sep 16.

14.

Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.

Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.

Mol Pharmacol. 2008 Mar;73(3):627-38. Epub 2007 Nov 19.

PMID:
18025070
15.

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.

Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR.

Cancer Res. 2006 Dec 15;66(24):11831-9.

16.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

Supplemental Content

Loading ...
Support Center